Targeting Protein Misfolding Congress | Kisaco Research

Targeting Misfolding Protein Congress

Exploring modulation and stabilization of aberrant and misfolded proteins through targeted small molecule therapeutics

Download Agenda
Virtual Summit
15-17 March, 2021

“This meeting is an excellent opportunity to interact with one of the best collections of thought leaders and drug discovery experts in the field of epitranscriptomics, and I am looking forward to exchanging strategic insights with my colleagues aiming at unlocking an entire class of previously undruggable targets”

Dr. Gerhard Mueller, Chief Scientific Officer, Gotham Therapeutics

FREE WEBINAR: Identifying and Developing Pharmacological Chaperones as Disease Modifying Therapeutic Candidates for Protein Misfolding Disease

Why Attend

With the neurological drug market now worth $86 billion, and the FDA set to reach a decision on Biogen’s Acudanimib in Spring, whether you’re focused on oncology, Alzheimer’s or ALS, it’s an exciting time to be targeting misfolding diseases.

Though there are currently no therapies and cures in this area of drug discovery due to several unmet drug discovery needs. The inaugural Targeting Protein Misfolding Congress will bring together academic and industry leaders, such as Anavex, Ionis Pharmaceuticals, Wren Therapeutics, Arizona State University and University of Florida, who are building platforms to identify and validate targets in protein misfolding diseases and intrinsically disordered proteins to combat these challenges:

  • The lack of appropriate disease models, physiological assays and blood biomarkers to evaluate translation aspects and target engagement.
  • Delivery mechanisms to deliver small molecules and biologics across the blood brain barrier.
  • Determining the true drivers and toxic species in protein misfolding diseases. 
  • Mapping the druggable hotspots on protein aggregates and intrinsically disordered proteins to target with small molecules.

Key outcomes this year include:

  • Improve pre-clinical predictability by learning what disease models are now considered best practice with Beth Hoffman, Founder and CEO, Origami Therapeutics and understand how Pfizer develops physiologically relevant assays for phenotypic screening.
  • Understand the underlying chemical biology of protein aggregation and the drivers behind misfolding diseases to help inform your target validation with Peter Lansbury, CSO, Lysosomal Therapeutics
  • Learn about the latest developments in delivery of biologics across the blood brain barrier as well as viral delivery advancements with Laura Ranum, Professor, University of Florida
  • Target your aggregate of choice after hearing Behnam Nabet, Research Fellow, Dana Farber Cancer Institute discuss novel approaches involving degradation
100+
Attendees
20+
Leading Speakers
3
Days of sharing the latest developments

Who Attends

30%
Pharma
30%
Biotech
30%
Academic & Research Institutes
10%
Service Providers

Pharma

Biotech

Academic & Research Institutes

Service Providers

Speakers

 

Johanne Kaplan

CDO
ProMIS Neurosciences

Johanne Kaplan

CDO
ProMIS Neurosciences

Johanne Kaplan

CDO
ProMIS Neurosciences
 

Abhishek Singharan

Assistant Professor
School of Molecular Sciences, Arizona State University

Abhishek Singharan

Assistant Professor
School of Molecular Sciences, Arizona State University

Abhishek Singharan

Assistant Professor
School of Molecular Sciences, Arizona State University
 

Tiago Outeiro

Professor
Universität Göttingen

Tiago Outeiro

Professor
Universität Göttingen

Tiago Outeiro

Professor
Universität Göttingen
 

Jack Rogers

Associate Professor of Psychiatry
HMS

Jack Rogers

Associate Professor of Psychiatry
HMS

Jack Rogers

Associate Professor of Psychiatry
HMS
 

Alberto Perez

Assistant Professor
University of Florida

Alberto Perez

Assistant Professor
University of Florida

Alberto Perez

Assistant Professor
University of Florida
 

Laura Ranum

Professor
University of Florida

Laura Ranum

Professor
University of Florida

Laura Ranum

Professor
University of Florida
 

Peter Lansbury

Chief Scientific Officer
Lysosomal Therapeutics

Peter Lansbury

Chief Scientific Officer
Lysosomal Therapeutics

Peter Lansbury

Chief Scientific Officer
Lysosomal Therapeutics
 

Beth Hoffman

CEO and Founder
Origami Therapeutics

Beth Hoffman

CEO and Founder
Origami Therapeutics

Beth Hoffman

CEO and Founder
Origami Therapeutics
 

Gene Yeo

Professor of Cellular and Molecular Medicine
UCSD

Gene Yeo

Professor of Cellular and Molecular Medicine
UCSD

Gene Yeo

Professor of Cellular and Molecular Medicine
UCSD
 

Hien Zhao

Director of Neuroscience Research
Ionis Pharmaceuticals

Hien Zhao

Director of Neuroscience Research
Ionis Pharmaceuticals

Hien Zhao

Director of Neuroscience Research
Ionis Pharmaceuticals
 

Alexander Scheer

CSO
Aelin Therapeutics

Alexander Scheer

CSO
Aelin Therapeutics

Alexander Scheer

CSO
Aelin Therapeutics
 

Chris Missling

President & CEO
Anavex Life Sciences

Chris Missling

President & CEO
Anavex Life Sciences

Chris Missling

President & CEO
Anavex Life Sciences
 

Rick Morimoto

Professor
Northwestern University

Rick Morimoto

Professor
Northwestern University

Rick Morimoto

Professor
Northwestern University
 

Michele Vendruscolo

CSO
Wren Therapeutics

Michele Vendruscolo

CSO
Wren Therapeutics

Michele Vendruscolo

CSO
Wren Therapeutics
 

Judith Frydman

Professor
Stanford University

Judith Frydman

Professor
Stanford University

Judith Frydman

Professor
Stanford University
 

Gergely Toth

Founder and CEO
Cantabio

Gergely Toth

Founder and CEO
Cantabio

Gergely Toth

Founder and CEO
Cantabio
 

Mark Reed

Founder
Treventis

Mark Reed

Founder
Treventis

Mark Reed

Founder
Treventis
 

Marcia Taylor

Vice President Research
Treventis

Dr. Marcia Taylor is the Vice President in charge of Research at Treventis Corporation. She has enabled key assays in the discovery of small molecules to prevent formation of toxic oligomers. She has led her team through small molecule synthesis, activity, DMPK, preclinical, and toxicity studies on the road to a disease modifying treatment for diseases of protein misfolding. Dr. Taylor received a PhD in Biochemistry and Molecular Biology from Dalhousie University.

Marcia Taylor

Vice President Research
Treventis

Marcia Taylor

Vice President Research
Treventis

Dr. Marcia Taylor is the Vice President in charge of Research at Treventis Corporation. She has enabled key assays in the discovery of small molecules to prevent formation of toxic oligomers. She has led her team through small molecule synthesis, activity, DMPK, preclinical, and toxicity studies on the road to a disease modifying treatment for diseases of protein misfolding. Dr. Taylor received a PhD in Biochemistry and Molecular Biology from Dalhousie University.

 

Behnam Nabet

Research Fellow
Dana-Farber Cancer Institute

Behnam Nabet

Research Fellow
Dana-Farber Cancer Institute

Behnam Nabet

Research Fellow
Dana-Farber Cancer Institute

Sponsors

Media Partners

Resources

Download Resource

The Agenda

Please download our 2021 agenda to find out more information about the congress including the main topics of discussion for the three days and preview lineup of speakers.

Download Full Agenda

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Registration ends in

Monday, February 15, 2021 to Wednesday, March 17, 2021
Academics
$399
Super Early Bird Extension rate
3 Day Conference Ticket
Access to the networking platform
Access to content on-demand 2 months post event
Monday, February 15, 2021 to Wednesday, March 17, 2021
Small Biotech (under 50 employees)
$599
Super Early Bird Extension rate
3 Day Conference Ticket
Access to the networking platform
Access to content on-demand 2 months post event
Monday, February 15, 2021 to Wednesday, March 17, 2021
Pharma
$899
Super Early Bird Extension rate
3 Day Conference Ticket
Access to the networking platform
Access to content on-demand 2 months post event
Monday, February 15, 2021 to Wednesday, March 17, 2021
Service Providers
$999
Super Early Bird Extension rate
3 Day Conference Ticket
Access to the networking platform
Access to content on-demand 2 months post event
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us